Videos

Sponsored
In this video, Dr Danilov discusses the use of acalabrutinib as a treatment option for patients with CLL, SLL, and MCL.
Sponsored
Dr Graff talks about how the CLL treatment landscape has evolved in recent years.
Sponsored
Dr Goy shares highlights of recent innovations in the treatment of patients with MCL.
Christina Baik, MD, MPH, shares insight on the efficacy and safety of HER3-DXs in EGFR-inhibitor resistant, EGFR-mutated NSCLC.
David O'Malley, MD, highlights promising results from a subgroup analysis of the effect of platinum sensitivity on the efficacy of rucaparib vs chemo for BRCA+, advanced, relapsed ovarian carcinoma.
Dr Krishnan shares findings from a phase 3 trial of teclistamab therapy for relapsed/refractory MM. These data were presented at the 2021 ASCO Annual Meeting.
Efstathios Kastritis, MD, shares findings from the ANDROMEDA study of subcutaneous daratumumab plus standard therapy for AL amyloidosis.
Saad Usmani, MD, shares findings from the CARTITUDE-1 study of ciltacabtagene autoleucel therapy for patients with R/R MM. These data are being presented at the 2021 ASCO Annual Meeting.
Stay in the know.
OncNet Newsletter